March 28, 2017
Xbrane Biopharma to deliver its cancer drug to Middle East
Xbrane Biopharma, a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables, has delivered its first batch of Spherotide to its partner in the Middle East to a value of €0.7 million.